Patient characteristics
| Variable . | All patients (n = 39) [N (%)]* . | Cohort 1, 2 mg-28/28 (n = 19) [N (%)] . | Cohort 2, 4 mg-21/28 (n = 20) [N (%)] . | P value . |
|---|---|---|---|---|
| Median age (years) | 61 | 63 | 61 | .68 |
| Male sex | 22 (56) | 10 (52) | 12 (60) | .64 |
| IgH type | .30 | |||
| IgG | 20 (51) | 8 (42) | 12 (60) | |
| IgA | 5 (13) | 4 (21) | 1 (5) | |
| Light chain only | 14 (36) | 7 (37) | 7 (35) | |
| IgL type | .73 | |||
| κ | 28 (72) | 13 (68) | 15 (75) | |
| Λ | 11 (28) | 6 (32) | 5 (25) | |
| Mean serum β2 microglobulin (mg/L) | 3.2 | 3.0 | 3.4 | .45 |
| Mean serum albumin (g/dL) | 3.9 | 3.9 | 3.9 | .65 |
| Lines of prior therapy (median) | 4 | 4 | 4 | .64 |
| Cytogenetics | ||||
| Deletion chromosome 17p† | 7 (18) | 4 (21) | 3 (15) | .64 |
| Chromosome 1q abnormalities | 18 (46) | 10 (55) | 8 (42) | .41 |
| Deletion chromosome 13 | 13 (33) | 5 (28) | 8 (42) | .36 |
| Len as most recent therapy | 15 (38) | 6 (32) | 9 (45) | .38 |
| Resistance to prior therapy | .99 | |||
| Len refractory | 39 (100) | 19 (100) | 20 (100) | |
| Len + bortezomib refractory | 31 (79) | 15 (79) | 16 (80) |
| Variable . | All patients (n = 39) [N (%)]* . | Cohort 1, 2 mg-28/28 (n = 19) [N (%)] . | Cohort 2, 4 mg-21/28 (n = 20) [N (%)] . | P value . |
|---|---|---|---|---|
| Median age (years) | 61 | 63 | 61 | .68 |
| Male sex | 22 (56) | 10 (52) | 12 (60) | .64 |
| IgH type | .30 | |||
| IgG | 20 (51) | 8 (42) | 12 (60) | |
| IgA | 5 (13) | 4 (21) | 1 (5) | |
| Light chain only | 14 (36) | 7 (37) | 7 (35) | |
| IgL type | .73 | |||
| κ | 28 (72) | 13 (68) | 15 (75) | |
| Λ | 11 (28) | 6 (32) | 5 (25) | |
| Mean serum β2 microglobulin (mg/L) | 3.2 | 3.0 | 3.4 | .45 |
| Mean serum albumin (g/dL) | 3.9 | 3.9 | 3.9 | .65 |
| Lines of prior therapy (median) | 4 | 4 | 4 | .64 |
| Cytogenetics | ||||
| Deletion chromosome 17p† | 7 (18) | 4 (21) | 3 (15) | .64 |
| Chromosome 1q abnormalities | 18 (46) | 10 (55) | 8 (42) | .41 |
| Deletion chromosome 13 | 13 (33) | 5 (28) | 8 (42) | .36 |
| Len as most recent therapy | 15 (38) | 6 (32) | 9 (45) | .38 |
| Resistance to prior therapy | .99 | |||
| Len refractory | 39 (100) | 19 (100) | 20 (100) | |
| Len + bortezomib refractory | 31 (79) | 15 (79) | 16 (80) |